US20040039030A1 - Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis - Google Patents
Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis Download PDFInfo
- Publication number
- US20040039030A1 US20040039030A1 US10/606,229 US60622903A US2004039030A1 US 20040039030 A1 US20040039030 A1 US 20040039030A1 US 60622903 A US60622903 A US 60622903A US 2004039030 A1 US2004039030 A1 US 2004039030A1
- Authority
- US
- United States
- Prior art keywords
- hydroxy
- formula
- pyridone
- employed
- surfactants
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C1=C([4*])N(O)C(=O)C([3*])=C1[2*] Chemical compound [1*]C1=C([4*])N(O)C(=O)C([3*])=C1[2*] 0.000 description 3
- ZVZAQFWMXCFBRV-UHFFFAOYSA-N CCCC1=CC=CC=C1.CC[Ar].C[Y] Chemical compound CCCC1=CC=CC=C1.CC[Ar].C[Y] ZVZAQFWMXCFBRV-UHFFFAOYSA-N 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
Definitions
- Seborrheic dermatitis is understood as meaning a disorder of the scalp which differs from simple dandruff by the presence of erythema as a sign of inflammation, by the greater degree of scaling with occasional itching and burning, and by the occurrence of eczematous changes to other body sites. It can occur in the form of patches, but also more frequently affects the whole scalp and often includes, beyond the hairline, the forehead, around the neck and the ears. In severe cases, the scalp can have a secondary infection, and the changes can then exhibit a spongy consistency, vesicle and crust formation and can weep.
- Seborrheic dermatitis frequently occurs even in infancy and usually remits spontaneously at an age of 8-12 months.
- the scalp changes consisting of erythema, scaling and occasionally vesicles and crusts in infants can regress spontaneously within a few weeks, intermittently reoccur or persist during the entire childhood. They are frequently combined with a similar. process around the eyelids, nose and ears. Later, the condition usually occurs after puberty and can last for the whole life or even increase in strength. Approximately 1-3% of the population are affected by this illness.
- corticosteroid preparations display their activity exclusively via an effect on the inflammatory process
- the antimycotic substances such as ketoconazole are active exclusively against the yeast fungi of the strain Pityrosporum which is assumed to be the cause of seborrheic dermatitis.
- the 1-hydroxy-2-pyridones according to the invention combine the properties of both classes of substance in one substance and exhibit both antiinflammatory action and antimycotic activity against Pityrosporum strains.
- the substances according to the invention in comparison to ketoconazole, the substances according to the invention —even afteronly a short topical contact time—concentrate rapidly in the skin layers which are relevant for fungal growth and thus contribute to a rapid cure.
- ketoconazole is inactive in vitro against gram-positive bacteria (Kinsman et al., J. Med. Microbiol. (1983) 16, No. 2, IV)
- the hydroxy-pyridones according to the invention exhibit activity against gram-positive and gram-negative aerobic and anaerobic bacteria (Dittmar et al., Arzneim.-Forschung, (1981) 31 (11), No. 8a, pp. 1317-1322). With respect to the treatment of secondarily infected cases, this is an extremely important finding.
- the compounds used according to the invention furthermore have very crucial. advantages with respect to their processing possibilities in pharmaceutical preparations. On account of their solubility in water, alcohols and aqueous-alcoholic solutions, the preparation of hair lotions and transparent gel preparations is possible without problems.
- the preparations according to the invention can also be employed for the treatment of Pityriasis versicolor, a superficial, noninflammatory skin fungus disorder on the trunk.
- the invention therefore relates to the use of 1-hydroxy-2-pyridones of the formula I
- R 1 , R 2 and R 3 which are identical or different, are a hydrogen atom or alkyl having 1-4 carbon atoms, and
- R 4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of the formula II
- X is S or O
- Y is a hydrogen atom or up to 2 halogen atoms such as chlorine and/or bromine,
- Z is a single bond or the bivalent radicals O, S, —CR 2 —(R ⁇ H or (C 1 -C 4 )-alkyl) or other bivalent radicals having 2-10 carbon and, if appropriate, oxygen and/or sulfur atoms linked in the form of a chain, where—if the radicals contain 2 or more oxygen and/or sulfur atoms—the latter must be separated from one another by at least 2 carbon atoms and where 2 adjacent carbon atoms can also be linked to one another by a double bond and the free valences of the carbon atoms are saturated by H and/or (C 1 -C 4 )-alkyl groups,
- Ar is an aromatic ring system having up to two rings which can be substituted by up to three radicals from the group consisting of fluorine, chlorine, bromine, methoxy, (C 1 -C 4 )-alkyl, trifluoromethyl and trifluoromethoxy, in free or in salt form,
- the carbon chain members are preferably CH 2 groups. If the CH 2 groups are substituted by C 1 -C 4 -alkyl groups, CH 3 and C 2 H 5 are preferred substituents.
- Exemplary radicals “Z” are:
- the radical “S” is a sulfur atom
- the radical “O” is an oxygen atom
- the term “Ar” denotes phenyl or fused systems such as naphthyl, tetrahydro- naphthyl and indenyl, and also isolated systems as such, which are derived from biphenyl, diphenylalkanes, diphenyl ethers and diphenyl thioethers.
- the hydrocarbon radial R 4 is an alkyl or cyclohexyl radical which can also be bonded to the pyridone ring via a methylene or ethylene group or can contain an endomethyl group.
- R 4 can also be an aromatic radical which, however, is preferably bonded to the pyridone radical via at least one aliphatic carbon atom.
- saturated in this case designates those radicals which contain no aliphatic multiple bonds, i.e. no ethylenic or acetylenic bonds.
- organic bases are used, poorly volatile bases are preferably employed, for example low molecular weight alkanolamines such as ethanolamine, diethanolamine, N-ethylethanolamine, N-methyidiethanolamine, triethanol-amine, diethylaminoethanol, 2-amino-2-methyl-n-propanol, dimethylamino-propanol, 2-amino-2-methylpropanediol, triisopropanolamine.
- alkanolamines such as ethanolamine, diethanolamine, N-ethylethanolamine, N-methyidiethanolamine, triethanol-amine, diethylaminoethanol, 2-amino-2-methyl-n-propanol, dimethylamino-propanol, 2-amino-2-methylpropanediol, triisopropanolamine.
- ethylenediamine hexamethylenediamine, morpholine, piperidine, piperazine, cyclohexylamine, tributylamine, dodecylamine, N,N-dimethyldodecylamine, stearylamine, oleylamine, benzylamine, dibenzylamine, N-ethylbenzylamine, dimethylstearylamine, N-methylmorpholine, N-methylpiperazine, 4-methylcyclohexylamine, N-hydroxyethylmorpholine.
- salts of quaternary ammonium hydroxides such as trimethylbenzylammonium hydroxide, tetramethylammonium hydroxide or tetraethylammonium hydroxide can also be used, furthermore guanidine and its derivatives, in particular its alkylation products.
- salt-forming agents for example, low molecular weight alkylamines such as methylamine, ethylamine or triethylamine.
- Suitable salts for the compounds to be employed according to the invention are also those with inorganic cations, for example alkali metal salts, in particular sodium, potassium or ammonium salts, alkaline earth metal salts such as, in particular, the magnesium or calcium salts, as well as salts with bi- or tetravalent cations, for example the zinc, aluminum or zirconium salt.
- alkali metal salts in particular sodium, potassium or ammonium salts
- alkaline earth metal salts such as, in particular, the magnesium or calcium salts
- salts with bi- or tetravalent cations for example the zinc, aluminum or zirconium salt.
- the active compounds to be employed in the preparations of the compound of the formula I can be prepared, for example, according to processes given in U.S. Pat. No. 2,540,218.
- liquid to semisolid pharmaceutical preparations in particular hair lotions, shampoos, liquid soaps, as well as cream, ointment and gel preparations, are suitable.
- the preparations according to the invention are present as shampoo, they can be in clear liquid or opaque liquid form, in cream form or even gelatinous.
- the surfactants on which these shampoos are based can be of anionic, cationic, nonionic or amphoteric nature and can also be present as a combination of these substances.
- anionic surfactants are employed on their own or as a mixture with other anionic surfactants as base surfactants - if appropriate with addition of amphoteric surfactants as cosurfactant.
- amphoteric surfactants are virtually insignificant, since their foaming behavior, thickenability and partly also skin and eye mucous membrane tolerability are only moderate. In combination with various anionic surfactants, however, precisely these properties are synergistically improved. This explains the relatively great importance of the amphoteric surfactants for the optimization of anionic shampoo bases.
- Nonionic surfactants can also be employed as cosurfactants.
- anionic detergent substances of this type which may be mentioned are: (C 10 -C 20 )-alkyl- and -alkylenecarboxylates, alkyl ether carboxylates, fatty alcohol sulfates, fatty alcohol ether sulfates, alkylol-amide sulfates and sulfonates, fatty acid alkylamide polyglycol ether sulfates, alkanesulfonates and hydroxyalkanesulfonates, olefinsulfonates, acyl esters of isothionates, ⁇ -sulfofatty acid esters, alkylbenzosulfonates, alkylphenol glycol ether sulfonates, sulfosuccinates, sulfosuccinic acid hemiesters and diesters, fatty alcohol ether phosphates, protein-fatty acid condensation products, alkylmonoglyceride sulfates
- amphoteric surfactants which can be added to the shampoos are: N-((C 12 -C 18 )-alkyl)- ⁇ -aminopropionates and N-((C 12 -C 18 )-alkyl)- ⁇ -iminodipropionates as alkali metal and mono-, di- and trialkylol-ammonium salts; N-acylamidoalkyl-N,N-dimethylacetobetaine, preferably N-((C 8 -C 18 )-acyl)amidopropyl-N,N-dimethylacetobetaine; (C 12 -C 18 )-alkyl-dimethylsulfopropylbetaine; amphoteric surfactants based on imidazoline (trade name: Miranol®, Steinapon®), preferably the sodium salt of 1-( ⁇ -carboxymethyloxyethyl)-1-(carboxymethyl)-2-laurylimidazo
- Suitable nonionic surfactants which can be employed as detergent substances are, for example: fatty alcohol ethoxylates (alkyl polyethylene glycols); alkylphenol polyethylene glycols; alkylmercaptan. polyethylene glycols; fatty amine ethoxylates (alkylamino polyethylene glycols); fatty acid ethoxylates (acyl polyethylene glycols), polypropylene glycol ethoxylates (Pluronic®); fatty acid alkylolamides (fatty acid amide polyethylene glycols); sucrose esters; alkyl polyglucosides; sorbitol esters and polyglycol ether.
- Suitable cationic surfactants are, for example, quaternary ammonium salts such as di-((C 10 -C 24 )-alkyl)dimethylammonium chloride or bromide, preferably di-((C 12 -C 18 )-alkyl)dimethylammonium choride or bromide; (C 10 -C 24 )-alkyldimethylethylammonium chloride or bromide; (C 10 -C 24 )-alkyltrimethylammonium chloride or bromide, preferably cetyltrimethyl-ammonium chloride or bromide and (C 20 -C 22 )-alkyltrimethylammonium chloride or bromide; (C 10 -C 24 )-alkyldimethylbenzylammonium chloride or bromide; preferably (C 12 -C 18 )-alkyldimethylbenzylammonium chloride; N-((C 10 -C 18 )-
- the preparations according to the invention can additionally contain further additives, e.g. aromatic substances, cblorants, opacifiers and pearl luster agents, for example esters of fatty acids and polyols, magnesium and zinc salts of fatty acids, dispersions based on copolymers, thickeners such as sodium, potassium or ammonium chloride, sodium sulfate, fatty acid alkylolamides, cellulose derivatives of natural gums, collagen hydrolyzates, furthermore fats, oils, fatty alcohols, silicones, substances having a keratolytic and keratoplastic action. for example sulfur, salicylic acid or enzymes.
- aromatic substances e.g. aromatic substances, cblorants, opacifiers and pearl luster agents
- esters of fatty acids and polyols for example esters of fatty acids and polyols, magnesium and zinc salts of fatty acids, dispersions based on copolymers, thickeners such as sodium, potassium or ammonium
- the shampoos are prepared in a manner known per se by mixing together of the individual components and a further processing—if necessary —suited to the particular type of preparation. Some of these various possible preparations are described by way of example in the working examples.
- the preparations according to the invention can also be present in the form of aqueous and aqueous-alcoholic hair lotions, and also those in gel form and in aerosol form as spray or foam.
- Alcohols employed are preferably ethanol and isopropyl alcohol.
- the pH of the preparations is in the skin-physiological range of approximately pH 4.5 to 6.5. Whereas, when using the compounds in salt form, the adjustment of the pH range mentioned has to be carried out using organic acids, this measure is not necessary when using the free compounds.
- the active compounds is incorporated in amounts which are customarily between approximately 0.05 and approximately 10%. Within this range, the concentrations of the specific preparations depend on their intended use. Certain preparation forms such as concentrates, which are to be diluted before use, can have considerably higher concentrations.
- concentrations will be employed, for example from about 0.05% to about 1%, preferably from 0.1 to 0.5%. In higher concentrations, they will expediently be used when they are preparations which, optionally after dilution, only act on the scalp for a short time, for example shampoos or liquid soaps. In these cases, for example, concentrations of approximately 0.2 to approxi- mately 10%, preferably from approximately 0.5% to approximately 2%, can be expedient.
- a preparation according to the invention has the following composition:
- a preparation according to the invention has the following composition:
- a preparation according to the invention has the following composition:
- a preparation according to the invention has the following composition:
- Liquid soap 1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone 1.00% Sodium lauryl diglycol ether sulfate (27% strength solution) 35.00%
- Cocamidopolyglycol ether sulfate magnesium salt (30% strength 8.00% solution)
- Cocamidopropylbetaine (30% strength solution) 10.00%
- a preparation according to the invention has the following composition:
- a preparation according to the invention has the following composition:
- a preparation according to the invention has the following composition:
- Cream preparation 1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)-pyridone, 1.00% aminoethatnol salt 1:1 2-Octyldodecanol 7.50% Liquid paraffin 7.50% Stearyl alcohol 7.50% Cetyl alcohol 7.50% Polysorbate 60 3.00% Sorbitan monostearate 2.00% Lactic acid, 90% strength 0.51% Water 63.49%
Abstract
Description
- Seborrheic dermatitis is understood as meaning a disorder of the scalp which differs from simple dandruff by the presence of erythema as a sign of inflammation, by the greater degree of scaling with occasional itching and burning, and by the occurrence of eczematous changes to other body sites. It can occur in the form of patches, but also more frequently affects the whole scalp and often includes, beyond the hairline, the forehead, around the neck and the ears. In severe cases, the scalp can have a secondary infection, and the changes can then exhibit a spongy consistency, vesicle and crust formation and can weep.
- Seborrheic dermatitis frequently occurs even in infancy and usually remits spontaneously at an age of 8-12 months. The scalp changes consisting of erythema, scaling and occasionally vesicles and crusts in infants can regress spontaneously within a few weeks, intermittently reoccur or persist during the entire childhood. They are frequently combined with a similar. process around the eyelids, nose and ears. Later, the condition usually occurs after puberty and can last for the whole life or even increase in strength. Approximately 1-3% of the population are affected by this illness.
- It is known that 1-hydroxy-2-pyridones and their salts exhibit activity against normal dandruff which is characterized by a clinically noninflammatory scaling of the scalp occurring in nearly all people (DE 22 34 009).
- The most promising type of treatment of seborrheic dermatitis until now was the topical application of corticosteroid preparations, but more recently topical therapy with antimycotic substances has gained importance.
- While corticosteroid preparations display their activity exclusively via an effect on the inflammatory process, the antimycotic substances such as ketoconazole are active exclusively against the yeast fungi of the strain Pityrosporum which is assumed to be the cause of seborrheic dermatitis. The 1-hydroxy-2-pyridones according to the invention, however, combine the properties of both classes of substance in one substance and exhibit both antiinflammatory action and antimycotic activity against Pityrosporum strains.
- In comparison to ketoconazole, the substances according to the invention —even afteronly a short topical contact time—concentrate rapidly in the skin layers which are relevant for fungal growth and thus contribute to a rapid cure.
- While ketoconazole is inactive in vitro against gram-positive bacteria (Kinsman et al., J. Med. Microbiol. (1983) 16, No. 2, IV), the hydroxy-pyridones according to the invention exhibit activity against gram-positive and gram-negative aerobic and anaerobic bacteria (Dittmar et al., Arzneim.-Forschung, (1981) 31 (11), No. 8a, pp. 1317-1322). With respect to the treatment of secondarily infected cases, this is an extremely important finding.
- Compared with ketoconazole, the compounds used according to the invention furthermore have very crucial. advantages with respect to their processing possibilities in pharmaceutical preparations. On account of their solubility in water, alcohols and aqueous-alcoholic solutions, the preparation of hair lotions and transparent gel preparations is possible without problems.
- The preparations according to the invention can also be employed for the treatment of Pityriasis versicolor, a superficial, noninflammatory skin fungus disorder on the trunk.
-
- in which R1, R2 and R3, which are identical or different, are a hydrogen atom or alkyl having 1-4 carbon atoms, and
-
- where
- X is S or O,
- Y is a hydrogen atom or up to 2 halogen atoms such as chlorine and/or bromine,
- Z is a single bond or the bivalent radicals O, S, —CR2—(R═H or (C1-C4)-alkyl) or other bivalent radicals having 2-10 carbon and, if appropriate, oxygen and/or sulfur atoms linked in the form of a chain, where—if the radicals contain 2 or more oxygen and/or sulfur atoms—the latter must be separated from one another by at least 2 carbon atoms and where 2 adjacent carbon atoms can also be linked to one another by a double bond and the free valences of the carbon atoms are saturated by H and/or (C1-C4)-alkyl groups,
- Ar is an aromatic ring system having up to two rings which can be substituted by up to three radicals from the group consisting of fluorine, chlorine, bromine, methoxy, (C1-C4)-alkyl, trifluoromethyl and trifluoromethoxy, in free or in salt form,
- for the production of a pharmaceutical for the treatment of seborrheic dermatitis.
- In the radicals “Z”, the carbon chain members are preferably CH2 groups. If the CH2 groups are substituted by C1-C4-alkyl groups, CH3 and C2H5 are preferred substituents. Exemplary radicals “Z” are:
- —O—, —S—, —CH2—, —(CH2)m—(m=2-10), —C(CH3)2—, —CH2O—, —OCH2—, —CH2S—, —SCH2—, —SCH(C2H5)—, —CH═CH—CH2O—, —O—CH2—CH═CH—CH2O—, —OCH2—CH2O—, —OCH2—CH2CH2O—, —SCH2CH2CH2S—, —SCH2CH2CH2CH2O—, —SCH2CH2OCH2CH2O —, —SCH2CH2OCH2CH2O —CH2CH2S— or —S—CH2—C(CH3)2—CH2—S—.
- The radical “S” is a sulfur atom, the radical “O” is an oxygen atom. The term “Ar” denotes phenyl or fused systems such as naphthyl, tetrahydro- naphthyl and indenyl, and also isolated systems as such, which are derived from biphenyl, diphenylalkanes, diphenyl ethers and diphenyl thioethers.
- In the formula I, the hydrocarbon radial R4 is an alkyl or cyclohexyl radical which can also be bonded to the pyridone ring via a methylene or ethylene group or can contain an endomethyl group. R4 can also be an aromatic radical which, however, is preferably bonded to the pyridone radical via at least one aliphatic carbon atom.
- Important representatives of the class of compounds characterized by the formula I are:
- 6-[4-(4-chlorophenoxy)phenoxymethyl]-1-hydroxy-4-methyl-2-pyridone, 6-[4-(2,4-dichlorophenoxy)phenoxymethyl]-1-hydroxy4-methyl-2-pyridone, 6-(biphenyl4-oxymethyl)-1-hydroxy4-methyl-2-pyridone, 6-(4-benzyl-phenoxymethyl)-1-hydroxy4-methyl-2-pyridone, 6-[4-(2,4-dichlorobenzyl-oxy)phenoxymethyl]-1-hydroxy4-methyl-2-pyridone, 6-[4-(4-chloro-phenoxy)phenoxymethyl]-1-hydroxy-3,4-dimethyl-2-pyridone, 6-[4-(2,4-dichlorobenzyl)phenoxymethyl]-1-hydroxy-3,4-dimethyl-2-pyridone, 6-[4-cinnamyloxy)phenoxymethyl]-1-hydroxy4-methyl-2-pyridone, 1-hydroxy4-methyl-6-[4-(4-trifluoromethylphenoxy)phenoxymethyl]-2-pyridone, 1hydroxy-4-methyl-6-cyclohexyl-2-pyridone, 1-hydroxy4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone, 1-hydroxy4-methyl-6-n-hexyl-, -6-iso-hexyl-, -6-n-heptyl- or -6-isoheptyl-2-pyridone, 1-hydroxy4-methyl-6-octyl- or -6-isooctyl-2-pyridone, in particular 1-hydroxy4-methyl-6-cyclohexyl-methyl- or -6-cyclohexylethyl-2-pyridone, where the cyclohexyl radical can in each case also carry a methyl radical, 1-hydroxy4-methyl-6-(2-bicyclo-[2,2,1]heptyl)-2-pyridone, 1-hydroxy-3,4-dimethyl-6-benzyl- or -6-dimethyl-benzyl-2-pyridone or 1-hydroxy4-methyl-6-(β-phenylethyl)-2-pyridone.
- The term “saturated” in this case designates those radicals which contain no aliphatic multiple bonds, i.e. no ethylenic or acetylenic bonds.
- The abovementioned compounds of the formula I can be employed either in free form or as salts, use in free form is preferred.
- If organic bases are used, poorly volatile bases are preferably employed, for example low molecular weight alkanolamines such as ethanolamine, diethanolamine, N-ethylethanolamine, N-methyidiethanolamine, triethanol-amine, diethylaminoethanol, 2-amino-2-methyl-n-propanol, dimethylamino-propanol, 2-amino-2-methylpropanediol, triisopropanolamine. Further poorly volatile bases which may be mentioned are, for example, ethylenediamine, hexamethylenediamine, morpholine, piperidine, piperazine, cyclohexylamine, tributylamine, dodecylamine, N,N-dimethyldodecylamine, stearylamine, oleylamine, benzylamine, dibenzylamine, N-ethylbenzylamine, dimethylstearylamine, N-methylmorpholine, N-methylpiperazine, 4-methylcyclohexylamine, N-hydroxyethylmorpholine. The salts of quaternary ammonium hydroxides such as trimethylbenzylammonium hydroxide, tetramethylammonium hydroxide or tetraethylammonium hydroxide can also be used, furthermore guanidine and its derivatives, in particular its alkylation products. However, it is also possible to employ as salt-forming agents, for example, low molecular weight alkylamines such as methylamine, ethylamine or triethylamine. Suitable salts for the compounds to be employed according to the invention are also those with inorganic cations, for example alkali metal salts, in particular sodium, potassium or ammonium salts, alkaline earth metal salts such as, in particular, the magnesium or calcium salts, as well as salts with bi- or tetravalent cations, for example the zinc, aluminum or zirconium salt.
- The active compounds to be employed in the preparations of the compound of the formula I can be prepared, for example, according to processes given in U.S. Pat. No. 2,540,218.
- For the use according to the invention of the compounds mentioned, liquid to semisolid pharmaceutical preparations, in particular hair lotions, shampoos, liquid soaps, as well as cream, ointment and gel preparations, are suitable.
- In this case, these are always preparations which, depending on their actual intended use, are applied to the skin and/or to the scalp for a shorter or longer time. Due to the addition of the compounds according to the invention, an effective treatment of the seborrheic dermatitis is brought about.
- If the preparations according to the invention are present as shampoo, they can be in clear liquid or opaque liquid form, in cream form or even gelatinous. The surfactants on which these shampoos are based can be of anionic, cationic, nonionic or amphoteric nature and can also be present as a combination of these substances.
- Preferably, however, anionic surfactants are employed on their own or as a mixture with other anionic surfactants as base surfactants - if appropriate with addition of amphoteric surfactants as cosurfactant.
- As the sole detergent substances, amphoteric surfactants are virtually insignificant, since their foaming behavior, thickenability and partly also skin and eye mucous membrane tolerability are only moderate. In combination with various anionic surfactants, however, precisely these properties are synergistically improved. This explains the relatively great importance of the amphoteric surfactants for the optimization of anionic shampoo bases.
- Nonionic surfactants can also be employed as cosurfactants.
- Examples of anionic detergent substances of this type which may be mentioned are: (C10-C20)-alkyl- and -alkylenecarboxylates, alkyl ether carboxylates, fatty alcohol sulfates, fatty alcohol ether sulfates, alkylol-amide sulfates and sulfonates, fatty acid alkylamide polyglycol ether sulfates, alkanesulfonates and hydroxyalkanesulfonates, olefinsulfonates, acyl esters of isothionates, α-sulfofatty acid esters, alkylbenzosulfonates, alkylphenol glycol ether sulfonates, sulfosuccinates, sulfosuccinic acid hemiesters and diesters, fatty alcohol ether phosphates, protein-fatty acid condensation products, alkylmonoglyceride sulfates and sulfonates, alkylglyceride ether sulfonates, fatty acid methyltaurides, fatty acid sarcosinates or sulforicinoleates. These compounds and their mixtures are used in the form of their water-soluble or water-dispersible salts, for example the sodium, potassium, magnesium, ammonium, mono-, di- and triethanolammonium as well as analogous alkylolammonium salts.
- Examples of amphoteric surfactants which can be added to the shampoos are: N-((C12-C18)-alkyl)-β-aminopropionates and N-((C12-C18)-alkyl)-β-iminodipropionates as alkali metal and mono-, di- and trialkylol-ammonium salts; N-acylamidoalkyl-N,N-dimethylacetobetaine, preferably N-((C8-C18)-acyl)amidopropyl-N,N-dimethylacetobetaine; (C12-C18)-alkyl-dimethylsulfopropylbetaine; amphoteric surfactants based on imidazoline (trade name: Miranol®, Steinapon®), preferably the sodium salt of 1-(β-carboxymethyloxyethyl)-1-(carboxymethyl)-2-laurylimidazolinium; amine oxides, e.g. (C12-C18)-alkyldimethylamine oxide or fatty acid amidoalkyldimethylamine oxide.
- Suitable nonionic surfactants which can be employed as detergent substances are, for example: fatty alcohol ethoxylates (alkyl polyethylene glycols); alkylphenol polyethylene glycols; alkylmercaptan. polyethylene glycols; fatty amine ethoxylates (alkylamino polyethylene glycols); fatty acid ethoxylates (acyl polyethylene glycols), polypropylene glycol ethoxylates (Pluronic®); fatty acid alkylolamides (fatty acid amide polyethylene glycols); sucrose esters; alkyl polyglucosides; sorbitol esters and polyglycol ether.
- Suitable cationic surfactants are, for example, quaternary ammonium salts such as di-((C10-C24)-alkyl)dimethylammonium chloride or bromide, preferably di-((C12-C18)-alkyl)dimethylammonium choride or bromide; (C10-C24)-alkyldimethylethylammonium chloride or bromide; (C10-C24)-alkyltrimethylammonium chloride or bromide, preferably cetyltrimethyl-ammonium chloride or bromide and (C20-C22)-alkyltrimethylammonium chloride or bromide; (C10-C24)-alkyldimethylbenzylammonium chloride or bromide; preferably (C12-C18)-alkyldimethylbenzylammonium chloride; N-((C10-C18)-alkyl)pyridinium chloride or bromide, preferably N-((C12-C16)-alkyl)pyridinium chloride or bromide; N-((C10-C18)-alkyl)isoquinolinium chloride, bromide or monoalkylsulfate; N-((C12-C18)-alkylolaminoformyl-methyl)pyridinium chloride; N-((C12-C18)-alkyl)-N-methylmorpholinium chloride, bromide or monoalkylsulfate, N-((C12-C18)-alkyl)-N-ethyl-morpholinium chloride, bromide or monoalkylsulfate; (C16-C18)-alkyl-pentaoxethylammonium chloride; diisobutylphenoxyethoxyethyldimethyl-benzylammonium chloride; salts of N,N-diethylaminoethylstearylamide and -oleylamide with hydrochloric acid, acetic acid, lactic acid, citric acid, phosphoric acid; N-acylamidoethyl-N,N-diethyl-N-methylammonium chloride, bromide or monoalkylsulfate and N-acylamidoethyl-N,N-diethyl-N-benzylammonium chloride, bromide or monoalkylsulfate, where acyl is preferably stearyl or oleyl.
- The preparations according to the invention can additionally contain further additives, e.g. aromatic substances, cblorants, opacifiers and pearl luster agents, for example esters of fatty acids and polyols, magnesium and zinc salts of fatty acids, dispersions based on copolymers, thickeners such as sodium, potassium or ammonium chloride, sodium sulfate, fatty acid alkylolamides, cellulose derivatives of natural gums, collagen hydrolyzates, furthermore fats, oils, fatty alcohols, silicones, substances having a keratolytic and keratoplastic action. for example sulfur, salicylic acid or enzymes.
- The shampoos are prepared in a manner known per se by mixing together of the individual components and a further processing—if necessary —suited to the particular type of preparation. Some of these various possible preparations are described by way of example in the working examples.
- The preparations according to the invention can also be present in the form of aqueous and aqueous-alcoholic hair lotions, and also those in gel form and in aerosol form as spray or foam. Alcohols employed are preferably ethanol and isopropyl alcohol.
- Further preparations which may be mentioned in which the 1-hydroxy-2-pyridones can be used according to the invention are, for example, cream and ointment preparations, products which are primarily used for the treatment of hairless head and body parts.
- The preparation of all these preparations is also carried out—as already mentioned in the case of shampoo—in a manner known per se with addition of the active compound employed according to the invention. Of the abovementioned 1-hydroxy-2-pyridones, the preparations according to the invention can contain one compound or even several in combination.
- The pH of the preparations is in the skin-physiological range of approximately pH 4.5 to 6.5. Whereas, when using the compounds in salt form, the adjustment of the pH range mentioned has to be carried out using organic acids, this measure is not necessary when using the free compounds.
- In the preparations according to the invention, the active compounds is incorporated in amounts which are customarily between approximately 0.05 and approximately 10%. Within this range, the concentrations of the specific preparations depend on their intended use. Certain preparation forms such as concentrates, which are to be diluted before use, can have considerably higher concentrations.
- If they are preparations which remain on the skin and on the scalp, for example gel preparations, ointments, creams or hair lotions, lower concentrations will be employed, for example from about 0.05% to about 1%, preferably from 0.1 to 0.5%. In higher concentrations, they will expediently be used when they are preparations which, optionally after dilution, only act on the scalp for a short time, for example shampoos or liquid soaps. In these cases, for example, concentrations of approximately 0.2 to approxi- mately 10%, preferably from approximately 0.5% to approximately 2%, can be expedient.
- The following quantitative data relate to the weight, if not stated otherwise.
- A preparation according to the invention has the following composition:
- Shampoo (based on anionic detergent substances)
1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone 1.00% Sodium lauryl diglycol ether sulfate (27% strength solution) 40.00% Disodium lauryl polyglycol ether sulfosuccinate (33% strength 10.00% solution) Sodium chloride 2.50% Water 46.50% - A preparation according to the invention has the following composition:
- Shampoo (based on anionic detergent substance with amphoteric surfactant as cosurfactant)
1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone 1.00% Sodium lauryl diglycol ether sulfate (27% strength solution) 36.00% Cocamidopropylbetaine (30% strength solution) 6.00% Sodium chloride 3.30% Water 53.70% - A preparation according to the invention has the following composition:
- Shampoo (based on anionic detergent substance with nonionic surfactant as cosurfactant)
1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone 1.50% Sodium lauryl diglycol ether sulfate (27% strength solution) 30.00% Lauryl alcohol polyglucoside 8.00% Sodium chloride 2.00% Water 58.50% - A preparation according to the invention has the following composition:
- Liquid soap
1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone 1.00% Sodium lauryl diglycol ether sulfate (27% strength solution) 35.00% Cocamidopolyglycol ether sulfate magnesium salt (30% strength 8.00% solution) Cocamidopropylbetaine (30% strength solution) 10.00% Lauryl alcohol glycol ether 2.00% Sodium chloride 2.00% Water 42.00% - A preparation according to the invention has the following composition:
- Hair lotion
1-Hydroxy-4-methyl-6-[4-(4-chlorophenoxy)phenoxymethyl]- 0.05% 2(1H)pyridone 2-Propanol 60.00% Water 39.95% - A preparation according to the invention has the following composition:
- Gel preparation
1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone 0.75% 2-Propanol 15.00% 2-Octyldodecanol 7.50% Carbomer 4,000,000 0.50% Polysorbate 60 1.50% Sodium hydroxide 0.18% Water 74.57% - A preparation according to the invention has the following composition:
- Cream preparation
1-Hydroxy-4-methyl-6-cyclohexyl-2(1H)-pyridone, 1.00% aminoethatnol salt 1:1 2-Octyldodecanol 7.50% Liquid paraffin 7.50% Stearyl alcohol 7.50% Cetyl alcohol 7.50% Polysorbate 60 3.00% Sorbitan monostearate 2.00% Lactic acid, 90% strength 0.51% Water 63.49% - In a clinical study with a total of 180 patients, it was possible to show that the symptoms of seborrheic dermatitis of the scalp (severe scaling, inflammation, itching) can be effectively treated by a 1-2×weekly treatment with a 1% strength ciclopirox shampoo preparation over a period of 4 weeks.
- In a clinical study, it was possible to successfully treat 180 patients with seborrheic dermatitis of the scalp, of the face and of the upper body by application of a 0.77% strength ciclopirox gel preparation over a period of 4 weeks.
Claims (13)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/606,229 US20040039030A1 (en) | 1996-09-27 | 2003-06-26 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US12/563,774 US20110112150A2 (en) | 1996-09-27 | 2009-09-21 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US13/018,417 US7981909B2 (en) | 1996-09-27 | 2011-01-31 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US13/177,710 US8227490B2 (en) | 1996-09-27 | 2011-07-07 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US13/555,352 US20120329835A1 (en) | 1996-09-27 | 2012-07-23 | Use of 1-hydroxy-2- pyridones for the treatment of seborrheic dermatitis |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19639818A DE19639818A1 (en) | 1996-09-27 | 1996-09-27 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
DE19639818.5 | 1996-09-27 | ||
US7719498A | 1998-12-04 | 1998-12-04 | |
US10/606,229 US20040039030A1 (en) | 1996-09-27 | 2003-06-26 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09077194 Division | 1997-09-16 | ||
PCT/EP1997/005070 Division WO1998013009A2 (en) | 1996-09-27 | 1997-09-16 | Use of 1-hydroxy-2-pyridone for the treatment of seborrheic dermatitis |
US7719498A Division | 1996-09-27 | 1998-12-04 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/563,774 Continuation US20110112150A2 (en) | 1996-09-27 | 2009-09-21 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040039030A1 true US20040039030A1 (en) | 2004-02-26 |
Family
ID=31889135
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/606,229 Abandoned US20040039030A1 (en) | 1996-09-27 | 2003-06-26 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US12/563,774 Abandoned US20110112150A2 (en) | 1996-09-27 | 2009-09-21 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US13/018,417 Expired - Fee Related US7981909B2 (en) | 1996-09-27 | 2011-01-31 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US13/177,710 Expired - Fee Related US8227490B2 (en) | 1996-09-27 | 2011-07-07 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US13/555,352 Abandoned US20120329835A1 (en) | 1996-09-27 | 2012-07-23 | Use of 1-hydroxy-2- pyridones for the treatment of seborrheic dermatitis |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/563,774 Abandoned US20110112150A2 (en) | 1996-09-27 | 2009-09-21 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US13/018,417 Expired - Fee Related US7981909B2 (en) | 1996-09-27 | 2011-01-31 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US13/177,710 Expired - Fee Related US8227490B2 (en) | 1996-09-27 | 2011-07-07 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US13/555,352 Abandoned US20120329835A1 (en) | 1996-09-27 | 2012-07-23 | Use of 1-hydroxy-2- pyridones for the treatment of seborrheic dermatitis |
Country Status (1)
Country | Link |
---|---|
US (5) | US20040039030A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040081677A1 (en) * | 1996-09-27 | 2004-04-29 | Aventis Pharma Deutschland Gmbh. | Antimycotic gel having high active compound release |
US20060078579A1 (en) * | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US20060078580A1 (en) * | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US20110112153A1 (en) * | 1996-09-27 | 2011-05-12 | Manfred Bohn | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
WO2012075396A3 (en) * | 2010-12-02 | 2012-12-27 | The University Of Kansas | Prodrugs of 6-cyclohexyl-1-hydroxy-4- methylpyridin-2(1h)-one and derivatives thereof |
Citations (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3883545A (en) * | 1968-08-31 | 1975-05-13 | Hoechst Ag | Certain 1-hydroxy-2-pyridones |
US3968118A (en) * | 1968-08-31 | 1976-07-06 | Hoechst Aktiengesellschaft | Process for the manufacture of 1-hydroxy-2-pyridones |
US4185106A (en) * | 1972-07-11 | 1980-01-22 | Hoechst Aktiengesellschaft | Pyridones as antidandruff agents |
US4699924A (en) * | 1983-02-01 | 1987-10-13 | Lever Brothers Company | Skin treatment composition |
US4711775A (en) * | 1972-07-11 | 1987-12-08 | Hoechst Aktiengesellschaft | Cosmetic compositions |
US4797109A (en) * | 1988-02-25 | 1989-01-10 | Methode Electronics, Inc. | Coiled wire interconnector |
US4797409A (en) * | 1986-04-18 | 1989-01-10 | Hoechst Aktiengesellschaft | 1-hydroxy-2-pyridones, a process for their preparation, and medicaments which contain them, and intermediates formed in the preparation of the 1-hydroxy-2-pyridones |
US4957730A (en) * | 1985-12-19 | 1990-09-18 | Hoechst Aktiengesellschaft | Antimycotic nail varnish |
US5066484A (en) * | 1990-04-30 | 1991-11-19 | Revlon, Inc. | Nail enamels containing glyceryl, glycol or citrate esters |
US5071639A (en) * | 1988-03-22 | 1991-12-10 | Shiseido Company Ltd. | Nail cosmetic composition |
US5120530A (en) * | 1989-02-24 | 1992-06-09 | Hoffmann-La Roche Inc. | Antimicotic nail varnish containing amorolfine in quaternary ammonium acrylic copolymer |
US5132107A (en) * | 1986-07-07 | 1992-07-21 | Lange Bouke J | Two-phase cleansing, conditioning and medicinal treatment shampoo |
US5264206A (en) * | 1987-06-16 | 1993-11-23 | Hoechst Aktiengesellschaft | Nail lacquer with antimycotic activity, and a process for the preparation thereof |
US5346692A (en) * | 1992-04-10 | 1994-09-13 | Roehm Pharma Gmbh | Nail lacquer for the treatment of onychomycosis |
US5356907A (en) * | 1989-10-17 | 1994-10-18 | Roussel Uclaf | 1-cycloalkylpyridones as analgesics |
US5494658A (en) * | 1993-01-05 | 1996-02-27 | Hoechst Aktiengesellschaft | Antidandruff agents and cosmetic preparations |
US5495658A (en) * | 1993-07-16 | 1996-03-05 | Sanden Corp. | Method of making cylindrical ferromagnetic body and cover assembly for rotor of DC motor |
US5510100A (en) * | 1993-06-10 | 1996-04-23 | L'oreal | Oil-in-water emulsions containing an auto-emulsifiable composition based on a fatty alcohol and on an alkyl polyoside and a co-emulsifying agent |
US5603939A (en) * | 1992-11-12 | 1997-02-18 | L'oreal | Film-forming cosmetic composition based on a chlorinated graft copolymer resulting from the grafting of a chlorinated polyolefin and acrylic, styrene and/or vinyl type unsaturated monomers |
US5609854A (en) * | 1995-06-06 | 1997-03-11 | Elizabeth Arden Company, Division Of Conopco, Inc. | Thickened and stabilized cosmetic emulsion compositions |
US5612327A (en) * | 1993-09-01 | 1997-03-18 | Teijin Limited | 1α,24-(OH)2 -cholecalciferol emulsion composition and method for treating psoriasis |
US5650145A (en) * | 1994-05-05 | 1997-07-22 | L'oreal | Dermatological/cosmetic compositions comprising antifungal and antibacterial compounds and reduction of hair loss therewith |
US5675013A (en) * | 1993-10-18 | 1997-10-07 | Olin Corporation | 1-hydroxy-6-substituted pyridine-2-ones and 1-hydroxy-6-substituted pyridine-2-thiones for biocidal use |
US5683681A (en) * | 1994-04-07 | 1997-11-04 | L'oreal | Cosmetic compositions for application to the nail |
US5753600A (en) * | 1989-10-09 | 1998-05-19 | Kao Corporation | Liquid detergent composition |
US5756108A (en) * | 1994-11-10 | 1998-05-26 | L'oreal | Oily phase in an aqueous phase dispersion stabilized by cubic gel particles and method of making |
US5814322A (en) * | 1994-07-11 | 1998-09-29 | L'oreal | Gelled cosmetic and/or dermatological composition which is rich in solvent and which contains hollow particles, and its applications |
US5866105A (en) * | 1991-05-23 | 1999-02-02 | Novartis Ag | Pharmaceutical composition |
US6162420A (en) * | 1993-05-18 | 2000-12-19 | Hoechst Aktiengesellschaft | Use of glyceryl triacetate for treating onychomycoses |
US6455551B1 (en) * | 1996-10-30 | 2002-09-24 | Aventis Pharma Deutschland Gmbh | Use of 1-hydroxy-2-pyridones for treating mucosa diseases which are difficult to treat |
US6469033B1 (en) * | 1996-09-27 | 2002-10-22 | Aventis Pharma Deutschland Gmbh | Use of 1-hydroxy-2-pyridones for the treatment of skin diseases |
US6514490B2 (en) * | 1997-04-14 | 2003-02-04 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a cationic agent |
US20030086881A1 (en) * | 2000-03-09 | 2003-05-08 | Aventis Pharma Deutschland Gmbh | Antiinfective combinations and their use for the topical treatment of fungal infections of the toenails and fingernails |
US20040081677A1 (en) * | 1996-09-27 | 2004-04-29 | Aventis Pharma Deutschland Gmbh. | Antimycotic gel having high active compound release |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4172149A (en) | 1978-01-30 | 1979-10-23 | Westwood Pharmaceuticals, Inc. | Method for treating living skin exhibiting excessive sebum secretion |
JPS6040403B2 (en) | 1979-11-02 | 1985-09-11 | エスエス製薬株式会社 | Anti-dandruff cleansers or lotions |
DE3140954A1 (en) | 1981-10-15 | 1983-05-05 | Hoechst Ag | Use of 1-hydroxy-2-pyridones for the prophylaxis and treatment of acne |
JPS58113299A (en) | 1981-12-26 | 1983-07-06 | ライオン株式会社 | Shampoo composition |
US4948576A (en) | 1983-02-18 | 1990-08-14 | Johnson & Johnson Consumer Products, Inc. | Detergent compositions |
JPS6169721A (en) | 1984-09-13 | 1986-04-10 | Kao Corp | Antimycotic composition |
GB2180846A (en) * | 1985-09-27 | 1987-04-08 | Procter & Gamble Ltd | Anti-dandruff shampoo compositions |
GB8524508D0 (en) | 1985-10-04 | 1985-11-06 | Beecham Group Plc | Composition |
JPH01501143A (en) | 1985-11-04 | 1989-04-20 | ダ−マトロジカル・プロダクツ・オブ・テキサス | Film-forming pharmaceutical vehicles for application of drugs to the nails, pharmaceutical compositions based on these vehicles and methods of use of the same |
US5641475A (en) | 1987-05-15 | 1997-06-24 | Tristrata, Inc. | Antiodor, antimicrobial and preservative compositions and methods of using same |
LU86945A1 (en) | 1987-07-17 | 1989-03-08 | Oreal | PHARMACEUTICAL AND COSMETIC COMPOSITIONS BASED ON PYRIDONES AND ANTIBACTERIAL AGENTS |
LU86944A1 (en) | 1987-07-17 | 1989-03-08 | Oreal | COMPOSITION BASED ON HYDROXYPYRIDONE DERIVATIVES FOR REDUCING HAIR LOSS |
GB8724285D0 (en) | 1987-10-16 | 1987-11-18 | Procter & Gamble | Shampoo compositions |
EP0313305A3 (en) | 1987-10-22 | 1990-02-07 | The Procter & Gamble Company | Photoprotection compositions comprising chelating agents |
DE3738405A1 (en) | 1987-11-12 | 1989-05-24 | Henkel Kgaa | SEBOSUPPRESSIVE PREPARATIONS |
HU202098B (en) | 1988-08-05 | 1991-02-28 | Istvan Laczko | Nail polish remover without aceton |
DE3826914A1 (en) | 1988-08-09 | 1990-02-15 | Henkel Kgaa | COLOR STABILIZATION OF ANTIMICROBIAL PREPARATIONS |
US5116603A (en) | 1989-01-31 | 1992-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Oral antifungal preventative, and method of use |
FR2685638A1 (en) | 1991-12-31 | 1993-07-02 | Biorga Sa Laboratoires | Compositions for cosmetic and/or dermatological use, comprising a combination of pyrithione zinc, piroctone olamine and a derivative of collagen and of fatty acid |
FR2685867B1 (en) | 1992-01-07 | 1995-06-09 | Thorel Jean | COMPOSITIONS AGAINST DEQUAMATION OF THE SKIN AND SCALP. |
FR2694694B1 (en) | 1992-08-13 | 1994-10-28 | Thorel Jean Noel | Active composition for the treatment of psoriasis, in particular psoriasis of the scalp. |
JPH0680567A (en) | 1992-09-01 | 1994-03-22 | Kao Corp | Agent for prevention and treatment of dandruff |
BR9307019A (en) | 1992-09-08 | 1999-02-23 | Procter & Gamble | Substantially mild colorless shampoo composition |
DE4336434A1 (en) | 1993-10-26 | 1995-04-27 | Hoechst Ag | Pharmaceutical preparation for the parenteral, enteral and dermal administration of practically insoluble drugs and processes for their preparation |
US5480904A (en) | 1993-10-28 | 1996-01-02 | Eli Lilly And Company | Methods for inhibiting uterine fibrosis |
CA2177683C (en) | 1993-12-23 | 1999-12-28 | George Endel Deckner | Tissue moisturizing and antimicrobial compositions |
JP3103274B2 (en) | 1994-06-01 | 2000-10-30 | 花王株式会社 | Sebum secretion inhibitor |
FR2722689B1 (en) | 1994-07-20 | 1996-10-04 | Fabre Pierre Dermo Cosmetique | NOVEL COMBINATION PRODUCT COMPRISING AN ANTIFUNGAL AGENT AND CROTAMITON AS A POTENTIALIZER OF THE ACTIVITY OF THE ANTIFUNGAL AGENT, AND DERMATOLOGICAL AND / OR COSMETIC COMPOSITIONS COMPRISING THE SAME |
US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
AT408067B (en) | 1995-03-17 | 2001-08-27 | Gebro Pharma Gmbh | PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION AND METHOD FOR THE PRODUCTION THEREOF |
IL113057A (en) | 1995-03-21 | 1999-01-26 | Univ Ramot | Compositions for the treatment of dandruff |
US6075017A (en) * | 1995-03-21 | 2000-06-13 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Compositions for the treatment of dandruff |
PT865278E (en) | 1995-12-04 | 2002-10-31 | Aventis Pharma Gmbh | USES OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF THERAPEUTICALLY DIFFICULT DISEASES OF SKIN MUCOSITY |
DE19639818A1 (en) | 1996-09-27 | 1998-04-02 | Hoechst Ag | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US20040039030A1 (en) | 1996-09-27 | 2004-02-26 | Hoechst Akeengesellschaft | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
ATE238751T1 (en) | 1998-02-09 | 2003-05-15 | Macrochem Corp | ANTI-FUNGAL NAIL POLISH |
US6231875B1 (en) | 1998-03-31 | 2001-05-15 | Johnson & Johnson Consumer Companies, Inc. | Acidified composition for topical treatment of nail and skin conditions |
US6120756A (en) | 1998-08-19 | 2000-09-19 | Philip I. Markowitz | Topical anionic salicylate for disorders of the skin |
-
2003
- 2003-06-26 US US10/606,229 patent/US20040039030A1/en not_active Abandoned
-
2009
- 2009-09-21 US US12/563,774 patent/US20110112150A2/en not_active Abandoned
-
2011
- 2011-01-31 US US13/018,417 patent/US7981909B2/en not_active Expired - Fee Related
- 2011-07-07 US US13/177,710 patent/US8227490B2/en not_active Expired - Fee Related
-
2012
- 2012-07-23 US US13/555,352 patent/US20120329835A1/en not_active Abandoned
Patent Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3968118A (en) * | 1968-08-31 | 1976-07-06 | Hoechst Aktiengesellschaft | Process for the manufacture of 1-hydroxy-2-pyridones |
US3883545A (en) * | 1968-08-31 | 1975-05-13 | Hoechst Ag | Certain 1-hydroxy-2-pyridones |
US4185106A (en) * | 1972-07-11 | 1980-01-22 | Hoechst Aktiengesellschaft | Pyridones as antidandruff agents |
US4711775A (en) * | 1972-07-11 | 1987-12-08 | Hoechst Aktiengesellschaft | Cosmetic compositions |
US4699924A (en) * | 1983-02-01 | 1987-10-13 | Lever Brothers Company | Skin treatment composition |
US4957730A (en) * | 1985-12-19 | 1990-09-18 | Hoechst Aktiengesellschaft | Antimycotic nail varnish |
US4797409A (en) * | 1986-04-18 | 1989-01-10 | Hoechst Aktiengesellschaft | 1-hydroxy-2-pyridones, a process for their preparation, and medicaments which contain them, and intermediates formed in the preparation of the 1-hydroxy-2-pyridones |
US5132107A (en) * | 1986-07-07 | 1992-07-21 | Lange Bouke J | Two-phase cleansing, conditioning and medicinal treatment shampoo |
US5264206A (en) * | 1987-06-16 | 1993-11-23 | Hoechst Aktiengesellschaft | Nail lacquer with antimycotic activity, and a process for the preparation thereof |
US4797109A (en) * | 1988-02-25 | 1989-01-10 | Methode Electronics, Inc. | Coiled wire interconnector |
US5071639A (en) * | 1988-03-22 | 1991-12-10 | Shiseido Company Ltd. | Nail cosmetic composition |
US5120530A (en) * | 1989-02-24 | 1992-06-09 | Hoffmann-La Roche Inc. | Antimicotic nail varnish containing amorolfine in quaternary ammonium acrylic copolymer |
US5753600A (en) * | 1989-10-09 | 1998-05-19 | Kao Corporation | Liquid detergent composition |
US5356907A (en) * | 1989-10-17 | 1994-10-18 | Roussel Uclaf | 1-cycloalkylpyridones as analgesics |
US5395843A (en) * | 1989-10-17 | 1995-03-07 | Roussel-Uclaf | Pyridones |
US5559130A (en) * | 1989-10-17 | 1996-09-24 | Roussel Uclaf | Pyrrolidinyl pyridones for treating pain |
US5066484A (en) * | 1990-04-30 | 1991-11-19 | Revlon, Inc. | Nail enamels containing glyceryl, glycol or citrate esters |
US5866105A (en) * | 1991-05-23 | 1999-02-02 | Novartis Ag | Pharmaceutical composition |
US5346692A (en) * | 1992-04-10 | 1994-09-13 | Roehm Pharma Gmbh | Nail lacquer for the treatment of onychomycosis |
US5603939A (en) * | 1992-11-12 | 1997-02-18 | L'oreal | Film-forming cosmetic composition based on a chlorinated graft copolymer resulting from the grafting of a chlorinated polyolefin and acrylic, styrene and/or vinyl type unsaturated monomers |
US5494658A (en) * | 1993-01-05 | 1996-02-27 | Hoechst Aktiengesellschaft | Antidandruff agents and cosmetic preparations |
US6162420A (en) * | 1993-05-18 | 2000-12-19 | Hoechst Aktiengesellschaft | Use of glyceryl triacetate for treating onychomycoses |
US5510100A (en) * | 1993-06-10 | 1996-04-23 | L'oreal | Oil-in-water emulsions containing an auto-emulsifiable composition based on a fatty alcohol and on an alkyl polyoside and a co-emulsifying agent |
US5495658A (en) * | 1993-07-16 | 1996-03-05 | Sanden Corp. | Method of making cylindrical ferromagnetic body and cover assembly for rotor of DC motor |
US5612327A (en) * | 1993-09-01 | 1997-03-18 | Teijin Limited | 1α,24-(OH)2 -cholecalciferol emulsion composition and method for treating psoriasis |
US5675013A (en) * | 1993-10-18 | 1997-10-07 | Olin Corporation | 1-hydroxy-6-substituted pyridine-2-ones and 1-hydroxy-6-substituted pyridine-2-thiones for biocidal use |
US5683681A (en) * | 1994-04-07 | 1997-11-04 | L'oreal | Cosmetic compositions for application to the nail |
US5650145A (en) * | 1994-05-05 | 1997-07-22 | L'oreal | Dermatological/cosmetic compositions comprising antifungal and antibacterial compounds and reduction of hair loss therewith |
US5814322A (en) * | 1994-07-11 | 1998-09-29 | L'oreal | Gelled cosmetic and/or dermatological composition which is rich in solvent and which contains hollow particles, and its applications |
US5756108A (en) * | 1994-11-10 | 1998-05-26 | L'oreal | Oily phase in an aqueous phase dispersion stabilized by cubic gel particles and method of making |
US5609854A (en) * | 1995-06-06 | 1997-03-11 | Elizabeth Arden Company, Division Of Conopco, Inc. | Thickened and stabilized cosmetic emulsion compositions |
US6469033B1 (en) * | 1996-09-27 | 2002-10-22 | Aventis Pharma Deutschland Gmbh | Use of 1-hydroxy-2-pyridones for the treatment of skin diseases |
US20040081677A1 (en) * | 1996-09-27 | 2004-04-29 | Aventis Pharma Deutschland Gmbh. | Antimycotic gel having high active compound release |
US6455551B1 (en) * | 1996-10-30 | 2002-09-24 | Aventis Pharma Deutschland Gmbh | Use of 1-hydroxy-2-pyridones for treating mucosa diseases which are difficult to treat |
US6514490B2 (en) * | 1997-04-14 | 2003-02-04 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a cationic agent |
US20030086881A1 (en) * | 2000-03-09 | 2003-05-08 | Aventis Pharma Deutschland Gmbh | Antiinfective combinations and their use for the topical treatment of fungal infections of the toenails and fingernails |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060121118A1 (en) * | 1996-09-27 | 2006-06-08 | Aventis Pharma Deutschland Gmbh | Antimycotic gel having high active compound release |
US7026337B2 (en) | 1996-09-27 | 2006-04-11 | Aventis Pharma Deutschland Gmbh | Antimycotic gel having high active compound release |
US7981909B2 (en) | 1996-09-27 | 2011-07-19 | Medicis Pharmaceutical Corporation | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US20040081677A1 (en) * | 1996-09-27 | 2004-04-29 | Aventis Pharma Deutschland Gmbh. | Antimycotic gel having high active compound release |
US20110112153A1 (en) * | 1996-09-27 | 2011-05-12 | Manfred Bohn | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US20060078580A1 (en) * | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US7740875B2 (en) | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US7776349B2 (en) | 2004-10-08 | 2010-08-17 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US20060078577A1 (en) * | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US20060078579A1 (en) * | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
WO2012075396A3 (en) * | 2010-12-02 | 2012-12-27 | The University Of Kansas | Prodrugs of 6-cyclohexyl-1-hydroxy-4- methylpyridin-2(1h)-one and derivatives thereof |
US8609637B2 (en) | 2010-12-02 | 2013-12-17 | The University Of Kansas | Prodrugs of 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-(1H)-one and derivatives thereof |
US9243014B2 (en) | 2010-12-02 | 2016-01-26 | The University Of Kansas | Method of treatment with prodrugs of 6-cyclohexyl-1-hydroxy-4-methylpyridin in-2-1H-one and derivatives thereof |
Also Published As
Publication number | Publication date |
---|---|
US7981909B2 (en) | 2011-07-19 |
US20110269801A1 (en) | 2011-11-03 |
US20120329835A1 (en) | 2012-12-27 |
US20110112153A1 (en) | 2011-05-12 |
US8227490B2 (en) | 2012-07-24 |
US20110112150A2 (en) | 2011-05-12 |
US20100076031A1 (en) | 2010-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006176540A (en) | Medicated shampoo for treating seborrheic dermatitis | |
US4711775A (en) | Cosmetic compositions | |
US4960772A (en) | Benzoyl peroxide and quaternary ammonium based pharmaceutical and cosmetic compositions | |
US8227490B2 (en) | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis | |
JPS6220167B2 (en) | ||
JP2020525428A (en) | Topical composition | |
KR100564386B1 (en) | A pharmaceutical composition for the treatment of seborrhea containing 4-hydroxy-5-methoxy-4-[2-methyl-3-3-methyl-2-butenyl-2-oxiranyl]-1-oxaspiro[2,5]octan-6-one | |
US5494658A (en) | Antidandruff agents and cosmetic preparations | |
EP0276151B1 (en) | Dissolved composition of [benzo-1,2,4-thiadiazine]-1,1-dioxide for hair germination and hair growth promotion. | |
MXPA99002864A (en) | Use of 1-hydroxy-2-pyridone for the treatment of seborrheic dermatitis | |
JPS6040403B2 (en) | Anti-dandruff cleansers or lotions | |
JP2020525452A (en) | Topical composition | |
US20190015447A1 (en) | Hair growth composition | |
DK164892B (en) | Use of cyanoguanidines for producing a preparation for treating alopecia | |
JPH0232007A (en) | Hair tonic | |
JPH04364107A (en) | Hair tonic | |
JPH04364108A (en) | Hair tonic | |
JPH03178918A (en) | Hair tonic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HOECHST AKTIENGESELLSCHAFT;REEL/FRAME:017952/0728 Effective date: 20020304 Owner name: HOECHST AKTIENGESELLSCHAFT, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOHN, MANFRED;KRAEMER, KARL THEODOR;MARKUS, ASTRID;REEL/FRAME:017952/0637;SIGNING DATES FROM 19980515 TO 19980520 |
|
AS | Assignment |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:017946/0877 Effective date: 20050901 |
|
AS | Assignment |
Owner name: MEDICIS PHARMACEUTICAL CORPORATION, ARIZONA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SANOFI-AVENTIS DEUTSCHLAND GMBH;REEL/FRAME:022052/0292 Effective date: 20081101 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |